Cytosorbents (CTSO) Cash from Operations Growth (5y) (2015 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13.10% |
| Dec 31, 2025 | -35.46% |
| Sep 30, 2025 | 4.73% |
| Jun 30, 2025 | -22.68% |
| Mar 31, 2025 | -1.55% |
| Dec 31, 2024 | 10.71% |
| Sep 30, 2024 | 13.91% |
| Jun 30, 2024 | -8.50% |
| Mar 31, 2024 | -2.65% |
| Dec 31, 2023 | -18.80% |
| Sep 30, 2023 | -14.58% |
| Jun 30, 2023 | -16.06% |
| Mar 31, 2023 | -7.12% |
| Dec 31, 2022 | -67.13% |
| Sep 30, 2022 | -25.27% |
| Jun 30, 2022 | -33.68% |
| Mar 31, 2022 | -32.55% |
| Dec 31, 2021 | -38.46% |
| Sep 30, 2021 | -10.86% |
| Jun 30, 2021 | -1.16% |
| Mar 31, 2021 | -13.20% |
| Dec 31, 2020 | 13.82% |
| Sep 30, 2020 | -7.73% |
| Jun 30, 2020 | 22.39% |
| Mar 31, 2020 | -10.36% |
| Dec 31, 2019 | -14.54% |
| Sep 30, 2019 | -21.99% |
| Jun 30, 2019 | -16.90% |
| Mar 31, 2019 | -39.57% |
| Dec 31, 2018 | -19.68% |
| Sep 30, 2018 | -36.63% |
| Jun 30, 2018 | -26.32% |
| Mar 31, 2018 | -22.18% |
| Dec 31, 2017 | 11.68% |
| Sep 30, 2017 | -27.99% |
| Jun 30, 2017 | -10.44% |
| Mar 31, 2017 | -13.10% |
| Dec 31, 2016 | 0.54% |
| Sep 30, 2016 | -17.57% |
| Jun 30, 2016 | -13.24% |
| Mar 31, 2016 | -16.49% |
| Dec 31, 2015 | -27.21% |
| Sep 30, 2015 | -28.96% |